(Q44480315)

English

Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

L B Tankó

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

U Mouritzen

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

H J Lehmann

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

L Warming

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A Moelgaard

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

S Christgau

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

P Qvist

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

M Baumann

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

L Wieczorek

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

N Hoyle

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

C Christiansen

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

687-693

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Bisphosphonates for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly administration of alendronate: rationale and plan for clinical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates: preclinical aspects and use in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent cyclic tiludronate in the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900091-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S8756-3282(03)00091-7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44480315&oldid=2025302585"